Erasca, Inc. (ERAS)
- Previous Close
1.7900 - Open
1.7900 - Bid 1.8000 x 100
- Ask 1.8600 x 200
- Day's Range
1.7900 - 1.8800 - 52 Week Range
1.5100 - 3.3750 - Volume
320,642 - Avg. Volume
799,004 - Market Cap (intraday)
280.264M - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.50
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
www.erasca.comRecent News: ERAS
Performance Overview: ERAS
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ERAS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ERAS
Valuation Measures
Market Cap
280.26M
Enterprise Value
23.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.88
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.17
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.44%
Return on Equity (ttm)
-34.33%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-125.04M
Diluted EPS (ttm)
-0.8300
Balance Sheet and Cash Flow
Total Cash (mrq)
312.35M
Total Debt/Equity (mrq)
17.64%
Levered Free Cash Flow (ttm)
-104.91M